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INTRODUCTION
There is no clear definition of orphan 
symptoms. There is a group of symptoms 
that are seldom evaluated in most symptom 
assessment tools which can be considered 
as orphan symptoms.1 These are generally 
prevalent symptoms that are unaddressed in 
clinical practice, yet often not reported by the 
patients or by healthcare professionals.2
Orphan symptoms may be defined as symp-
toms not regularly assessed in clinical prac-
tice, and consequently little studied and not 
properly treated. No epidemiological or clin-
ical studies generally exist to gauge the prev-
alence of the symptoms chosen; nevertheless, 
these symptoms are distressing for patients 
and their families. Orphan symptoms remain 
unaddressed in clinical practice if not high-
lighted by the patient or specifically sought 
by the healthcare professional. These symp-
toms may have a significant impact on the 
remaining quality of life (QoL). In these 
guidelines, only selected orphan symptoms 
are discussed.
Among the most frequent orphan symp-
toms in patients with cancer that are related 
to the tumour or the antitumour treatment 
are muscle cramps, myoclonus, taste alter-
ations, xerostomia, cough, hiccup, rectal 
tenesmus and restless legs syndrome (RLS).
No epidemiological or clinical study exists 
regarding the prevalence of most orphan 
symptoms in patients with cancer. These 
symptoms are really distressing for patients 
and their families. Several case series and case 
reports, but very few prospective trials, have 
been published until now. For this reason, 
the levels of evidence (LoEs) and grades 
of recommendation (GoRs) are generally 
low. These European Society for Medical 
Oncology (ESMO) Clinical Practice Guide-
lines on management of orphan symptoms 
are the first approach for practical guidelines 
on this topic.
MUSCLE CRAMPS
A muscle cramp is a sudden, involuntary, 
painful contraction of a muscle or part of it, 
self- extinguishing within a few minutes; it is 
often accompanied by a palpable knotting of 
the muscle. The incidence of muscle cramps 
is usually low (<5%) but changes according to 
the stage of cancer disease, treatments (active 
antitumour treatments during innovative 
therapies and after surgery), setting of care 
(hospital, home), comorbidities of patients 
and the concomitant polypharmacotherapy.3 
Prospective studies evaluating muscle cramps 
in patients with cancer are lacking.
Muscular cramps can be caused by several 
pathogenic mechanisms related to disease: 
dehydration, electrolyte imbalance, vascular, 
anticancer as well as other drugs (ie, ator-
vastatin) and metabolic disorders. In a study 
evaluating 50 patients referred to a neuro- 
oncology unit for the onset of cramps, 
cancer- related or cancer treatment- related 
toxicity were identified as the cause in 84% 
of patients.3 In this study, peripheral neurop-
athies were identified as the principal cause 
of muscular cramps in 44% of the patients, 
spinal nerve roots abnormalities were present 
in 26% and plexus pathology in 8%.3 Poly-
myositis and cisplatin hypomagnesaemia 
occurred in <4% of patients.3
Other potential causes of cramps are 
tumour infiltration of nerve roots or brachial 
and lumbar sacral plexus and leptomeningeal 
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infiltration. Patients with cancer often suffer due to meta-
bolic (diabetes, thyroid disturbances) and electrolyte 
(hypomagnesaemia, hypokalaemia) alterations that can 
modify muscle contractility.3
A major toxic and dose- limiting effect of cisplatin is a 
sensory peripheral neuropathy due to the toxic effect of 
cisplatin on the dorsal root ganglion cells; the accumu-
lation of cisplatin in the extracellular space of muscle 
affects motor nerve and may induce muscle cramps.4
Oxaliplatin is also associated with cramps, as a direct 
manifestation of acute toxicity.5
Other neurotoxic agents like vinca alkaloids as well as 
hormonotherapy3 and biological drugs may be associ-
ated with cramps.3 A painful necrotising myopathy is a 
rare complication of vincristine whose manifestations are 
myalgia and cramps.6
Endocrine manipulation in breast and prostate cancer 
can induce cramps as well, and the incidence of cramps 
in these patients is unknown, but they have been reported 
with medroxyprogesterone acetate and tamoxifen. 
Several tyrosine kinase inhibitors have been associated 
with cramps with differences in incidence and severity. 
Muscle cramps are one of the major adverse events (AEs) 
of vismodegib. This effect is probably due to antagoni-
sation of the Hedgehog signalling pathway causing cell 
membrane calcium channel activation.7 Online supple-
mental table S1 shows examples of antineoplastic drugs 
potentially inducing cramps.
Treatment
The first step is the treatment of underlying causes of 
muscle cramps. Specific studies on the treatment of 
cramps in patients with cancer are lacking in literature. 
For this reason, all presented evidence is based on studies 
including non- cancer populations.
Non-pharmacological treatments
Several non- pharmacological therapies are suggested by 
physicians but there is little evidence supporting their 
use. Hydration is frequently recommended. However, 
there are no studies investigating its use and efficacy (IV, 
B). In a randomised study of 191 non- cancer patients 
comparing those who stretched their calves three times 
a day with patients instructed in moving the legs without 
stretching, no benefit of stretching on the frequency of 
cramps or number of cramp- free nights was found.8 Calf 
stretching is not helpful in reducing the frequency of 
muscle cramps (II, D).
Pharmacological treatments
Quinine derivatives
Based on data from two randomised non- cancer patient 
studies, quinine derivatives (hydroquinine hydrobromide 
dihydrate 300 mg at night) are effective in reducing the 
frequency of muscle cramps, although the magnitude of 
benefit is small.9 10 However, these agents are associated 
with side effects. The most common serious side effects 
reported were thrombotic thrombocytopaenic purpura, 
haemolytic uraemic syndrome, disseminated intravas-
cular coagulation and bleeding diathesis. The frequency 
of serious side effects was 2%–4%. Even if effective, the 
use of quinine derivatives for routine treatment of muscle 
cramps should be avoided and only be considered when 
the cramps are very disabling, with careful monitoring of 
potential side effects (II, D).
Gabapentin
In a double- blind, randomised controlled trial (RCT) of 
gabapentin (3600 mg a day) in 204 patients with amyo-
trophic lateral sclerosis, the evaluation of muscle cramps 
found no difference between the treatment group and 
placebo with respect to any symptom score.11 The use of 
gabapentin for cramps is not recommended (II, D).
Naftidrofuryl, vitamin B complex and diltiazem
Based on small randomised studies, naftidrofuryl (300 
mg two times per day), vitamin B complex (30 mg per 
day of vitamin B6) and diltiazem (30 mg per day of dilti-
azem hydrochloride) might be effective in the treatment 
of muscle cramps. In particular, naftidrofuryl demon-
strated to induce a significant reduction of cramps and an 
increase in cramp- free days (II, C). The study regarding 
vitamin B complex was a very small study of 28 patients 
showing that vitamin B complex (30 mg per day of 
vitamin B6) induced remission of muscle cramps in 86% 
of treated patients who were not known to be vitamin 
deficient compared with placebo, but the completion 
rate and compliance were not detailed in the study.12 For 
this reason, the results are unreliable. The use of vitamin 
B complex for the treatment of muscle cramps in patients 
with cancer cannot be routinely recommended (III, D). A 
double- blind, cross- over study of 13 patients investigated 
the effects of 30 mg of diltiazem hydrochloride on the 
number and intensity of cramps in patients experiencing 
≥2 cramps per week. This underpowered trial showed a 
reduction (−5.84 to −0.16 cramps per 2- week treatment 
phase, p=0.04) in the number of cramps over time in 
patients treated with diltiazem hydrochloride compared 
with placebo, with no effect on the intensity of cramps.13 
The use of diltiazem hydrochloride in reducing the 
number of cramps may exert some efficacy (III, C). Data 
regarding the use of magnesium (magnesium citrate 900 
mg per day or magnesium sulfate 300 mg per day) prepa-
rations showed that these agents are most likely not effec-
tive in the treatment of muscle cramps (III, D).14
In an extremely small study, nine patients with 
vismodegib- induced muscle cramps were treated with 
calcium channel blocker amlodipine besilate 10 mg per 
day for 2 weeks. During a period of 8 weeks, the percentage 
change in cramp frequency was significantly reduced by 
−5.81% per week (95% CI, −10.15% to −1.48%; p =0.009) 
with amlodipine treatment. Amlodipine may be effective 
in vismodegib- induced muscle cramps (IV, C).15
The American Society of Clinical Oncology Clinical 
Practice Guideline on chemotherapy (ChT)- induced 
peripheral sensory neurotoxicity does not recommend 
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any established agent for prevention or treatment of 
muscle cramps.16
Baclofen, carbamazepine and oxcarbazepine are 
frequently used in clinical practice for the treatment of 
muscle cramps but there are no clinical trials in the liter-
ature evaluating their efficacy for this indication.17 Only 
case reports in non- cancer populations reporting the use 
of these agents in the treatment of particular neuropathic 
conditions such as cramp- fasciculation syndrome have 
been published (V, C).17
Recommendations
 ► For vismodegib- induced cramps, amlodipine besilate 
10 mg per day (to be used with caution in patients 
with hypotension) is recommended (IV, C).
 ► Use of naftidrofuryl demonstrated a significant reduc-
tion in frequency of cramps and an increase in cramp- 
free days (II, C).
 ► Quinine 200–300 mg per day (II, D) is recommended.
MYOCLONUS
Myoclonus is defined as involuntary single or irregular 
repetitive movements of one part of the body, most 
frequently of the extremities, associated with either 
muscle contraction (positive myoclonus) or brief loss of 
muscle tone (negative myoclonus).18 Myoclonus occur-
ring in patients with cancer can be multifactorial. The 
most common causes include:
 ► Brain tumours—primary or metastatic.
 ► Metabolic causes (hyperglycaemia, hyponatraemia, 
renal or hepatic failure, hypercalcaemia and 
hypoglycaemia).
 ► Drug toxicity (opiates, cyclic antidepressants, selective 
serotonin reuptake inhibitors, monoamine oxidase 
inhibitors).
 ► Immune checkpoint inhibitors (myoclonus- ataxia 
syndrome has been described following treatment 
with immune checkpoint inhibitors, for example, with 
nivolumab plus ipilimumab or pembrolizumab).18
The main causes of this symptom are related to the 
use of medications acting at the central nervous system 
(CNS) or focal nervous system damage by primary 
tumours or metastases (or rarely paraneoplastic enceph-
alitis). The frequency of opioid- related myoclonus varies 
widely, ranging from 2.7% to 87% of the population, 
and this discrepancy is due to the different assessments 
of perception.19 Opioid- induced myoclonus is not dose- 
related, and both myoclonus and hyperalgesia have 
been reported to occur with various opioids following a 
variety of doses, treatment durations and administration 
routes.20
Hyperexcitability, hyperalgesia and myoclonus may 
be induced by high dose of intrathecal or systemic 
morphine.21 Several authors speculate that the neuro-
excitatory metabolites of opioids, such as morphine and 
hydromorphone metabolites, may be responsible for 
opioid- induced myoclonus and hyperalgesia.22 Generally, 
naloxone is not able to reverse central excitatory potency 
of morphine and its metabolites.23
Concomitant medications such as haloperidol or 
phenothiazine or neurotoxic antineoplastic agents may 
also have an influence on myoclonus manifestations.22
Treatment
There is a lack of data for myoclonus treatment in patients 
with cancer. Most articles are case reports or small series 
(placebo- controlled trials are not available). As a first 
step, all neuroleptic drugs should be reviewed and opioid 
rotation or dose reduction should be considered (V, B).22 
Hydration is recommended to reduce renal failure and 
accumulation of drug metabolites or to resolve electrolyte 
disorders (V, B).22
Benzodiazepines such as clonazepam, diazepam and 
anticonvulsants such as valproate have been suggested for 
the treatment of opioid- induced myoclonus as supported 
by the gamma- aminobutyric acid (GABA) mechanism of 
opioid toxicity (V, B).24
Clonazepam can be used with a starting dose of 0.5–1 
mg orally at bedtime or two times per day if neces-
sary.24 Continuous infusion of midazolam has also been 
successful and the short half- life of the drug allows for 
rapid titration to an effective dose; however, clonazepam 
leads to increased sedation (V, C).25
Dantrolene is a drug with a specific inhibitory mech-
anism on the calcium release at the sarcoplasmic retic-
ulum of the striated muscle and it has demonstrated in 
case reports only some effects at doses of 50–100 mg a 
day (V, C).26
Use of botulin toxin type A has been reported to be 
effective. Administration by injection into targeted 
muscles has been demonstrated to reversibly block the 
neuromuscular junction (V, C).27
Myoclonic spasms secondary to the intrathecal 
morphine have been controlled with oral baclofen, 
although doses and duration of treatment are not defined 
(V, C).28
Recommendations
 ► All neuroleptic drugs should be reviewed and opioid 
rotation or dose reduction should be considered (V, 
B).
 ► Benzodiazepines such as clonazepam and diaz-
epam and anticonvulsants such as valproate have 
been suggested for the treatment of opioid- induced 
myoclonus (V, B).
 ► Dantrolene 25–100 mg three times a day for a 
maximum of 7 days (V, C) is recommended.
 ► Botulin toxin type A 5–10 U per injection into targeted 
muscles (V, C) is recommended.
TASTE ALTERATIONS
Taste alterations occur as absence of taste sensation 
(ageusia), reduction in taste sensitivity (hypogeusia), 
increased sensitivity (hypergeusia) or distortion of the 
sense of taste (dysgeusia).
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In patients with cancer, altered taste perception is 
usually underestimated by clinicians and is hardly ever 
reported spontaneously by the patients. Dysgeusia has a 
large impact on food intake and consequently on weight 
loss, malnutrition, decreased enjoyment of a meal and 
QoL.29
The incidence of dysgeusia depends on the cancer 
type, localisation and on its treatments. Of all patients 
receiving ChT, radiotherapy (RT) or both, 50%–75% have 
experienced alterations of taste perception.30 In patients 
with head and neck cancer undergoing multimodality 
treatments, the incidence of dysgeusia reached percent-
ages between 75% and 100%.30 Prevalence estimates vary 
considering different measurement approaches.
A systematic review of 14 studies (where the presence 
of dysgeusia induced by cancer therapies was correctly 
assessed using a standardised and validated scale) reported 
that prevalence in the ChT group was 56.3%,66.5% in the 
RT group and 76% in the combined ChT and RT group. 
Approximately 15% of patients treated with head and 
neck RT had continuous dysgeusia even after the comple-
tion of treatment.31 Patients treated with RT had worse 
dysgeusia than ChT patients, and the severity was related 
with cumulative radiation dose and the onset of severe 
mucositis. Online supplemental table S2 shows examples 
of antineoplastic drugs potentially inducing dysgeusia.
Dysgeusia is a subjective symptom and can be assessed 
with the use of the Common Terminology Criteria for 
Adverse Events (CTCAE) 5.0 and the Subjective Total 
Taste Acuity Scale (ChT- induced Taste Alteration Scale).32 
Objective measures include the detection or recognition 
threshold values for the five fundamental tastes (sweet-
ness, bitterness, sourness, saltiness and umami) in two 
different ways: with the use of an instrument called an elec-
trogustometer (with electrical stimuli) or using threshold 
tests performed with natural stimuli.33 The heterogeneity 
of all used systems represents a limiting factor. No biolog-
ical markers are available. A recent review on taste disor-
ders states that there is no gold standard assessment tool 
for dysgeusia.34 Heterogeneity in study methods hinders 
conclusive identification of the most appropriate way to 
measure this symptom. Subjective measures may reflect 
the patient experience and more reliably predict changes 
in dietary behaviour. The aetiology of this disorder in 
patients with cancer is multifactorial. Tumour- related 
causes exist but the main source is related to cancer ther-
apies (see online supplemental table S3).
In particular, antineoplastic treatments may reduce 
the number of normal receptor cells, alter cell structures 
on receptors and stop neural coding.35 RT also damages 
salivary glands with consequent hyposalivation and xero-
stomia that, according to some authors, may exacerbate 
dysgeusia.36
ChT enters the mouth by diffusion through capillaries, 
giving an unpleasant taste or the ChT can directly destroy 
taste receptors. Dysgeusia has been reported to be most 
common among patients receiving taxanes, 5- fluorouracil 
and the oral analogue irinotecan.37 Patients treated with 
anthracyclines, platinum- based drugs and vinorelbine 
also suffered the highest frequencies for bad or metallic 
taste. Oxaliplatin- induced neurotoxicity could determine 
cold hypersensitivity.38 Other concomitant causes are 
documented in online supplemental table S3.
Recent research shows that tumours produce an inflam-
matory state through cytokines/chemokines that lead to 
cellular damage.36 In haematopoietic stem cell transplan-
tation, dysgeusia is related with the conditioning regi-
mens, supportive medications (antimicrobials, diuretics, 
antihypertensives), immunosuppressants, and infectious 
and allogenic- reactive complications.39 A new conceiv-
able mechanism, that needs to be investigated in the 
future, is the role of microbiota. Cancer therapies are 
usually linked with disrupted microbiota, while alter-
ations of microbiota are observed in oral cancer and lead 
to inflammation and taste disturbances.36
Treatment
While the origins of dysgeusia are multifactorial, there are 
dedicated approaches to minimise its impact on patients; 
once a cause has been identified, the corresponding strat-
egies should be adopted.
Pharmacological management strategies
Zinc supplementation
Zinc supplementation is one of the most common inter-
ventions studied for preventing and/or treating dysgeusia 
related to various causes, including cancer- related ther-
apies.40 It is the cofactor for alkaline phosphatase, the 
most abundant enzyme in the taste bud membrane. Zinc 
and other metals control the conformation of the protein 
(‘gatekeeper’) that regulates the passage of tastants 
through the taste bud pore. Although this element is 
closely associated with taste, trials using zinc, gluconate or 
sulfate in patients with cancer have reported conflicting 
results.
A randomised study that included 18 patients showed 
that zinc taken orally during RT for head and neck cancer 
limited the degree of objective and subjective taste distur-
bances and showed early recovered gustative acuity.41 In 
another pilot study involving 12 lung patients with cancer, 
a zinc- containing fluid was infused with ChT and the taste 
thresholds measured using an electrogustometer. No 
taste disorder was reported in the arm that received zinc 
supplementation.42
An orally bioavailable chelate composed of zinc and 
L- carnosine known as polaprezinc improved taste alter-
ations in 70% of patients with breast cancer that under-
went high- dose ChT.43 Similar results were observed in a 
randomised placebo- controlled trial where zinc sulfate 
prevented RT- induced taste alterations in patients with 
head and neck cancer. Taste acuity was determined by 
measuring detection and recognition thresholds for four 
taste qualities using the Henkin method.44 In the study 
by Halyard et al, 143 patients receiving RT±ChT for head 
and neck cancer were randomised to receive zinc sulfate 
orally or placebo starting on the first day of RT and for 
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4 weeks after RT completion. No statistically significant 
differences between the two groups in terms of taste alter-
ation (measured through subjective parameters) were 
found.45 Furthermore, one of the most recent trials (58 
patients included) comparing zinc with placebo for ChT- 
related taste alterations showed no significant difference 
between the two arms. The measurement of the improve-
ment in altered taste and smell was made using a 0–100 
scale.46
Zinc salts are well tolerated in most cases, they can cause 
dyspepsia and should be administered during meals to 
reduce these potential symptoms.
An excess intake of zinc may have negative effects on 
the immune system, so it must be used with caution when 
administered to immunocompromised patients with 
cancer46 and should only be limited to patients with a zinc 
deficiency (II, C).
Amifostine
Amifostine is an organic cytoprotective agent that plays 
a role in the protection of salivary gland function. Two 
randomised studies investigated its use in preventing 
dysgeusia: while amifostine may decrease the severity and 
incidence of acute and late gastrointestinal and other 
types of toxicities, it does not appear to decrease the 
occurrence of dysgeusia and may paradoxically increase 
it.47 48 Therefore, it is not recommended (II, D).
Other substances like glutamine, megestrol acetate 
(MGA) and the miracle fruit (Synsepalum dulcificum) 
were studied for the treatment of dysgeusia. Glutamine 
results showed no effect at preventing taxane- induced 
dysgeusia.49
MGA, a potent agonist of progesterone receptors, was 
administered daily in a randomised placebo control trial 
to weight- losing patients with advanced cancer experi-
encing taste disturbances. Findings supported the posi-
tive outcome on dysgeusia in the MGA group, but the 
trial had several limitations.50
Miraculin, a glycoprotein extracted from the fruit of 
Synsepalum dulcificum, when used as a sugar substitute 
improved the taste in patients with cancer in two very 
small (eight patients) pilot studies.51 These studies indi-
cated that miracle fruit improved patients’ taste percep-
tion, which might ultimately lead to better eating. Further 
research is necessary before it can be recommended in 
patients with taste alterations.
Dronabinol (delta-9- tetrahydrocannabinol, 2.5 mg) 
showed promising results in a phase II randomised 
double- blind placebo- controlled study, so it may be useful 
in treating taste alteration and increasing oral intake of 
food.52 These preliminary results require further confir-
mation studies with larger randomised trials.
Non-pharmacological management strategies
Self-care strategies
Previous studies suggested the importance of information 
about self- management, teaching and education to treat 
dysgeusia. Observational trials proposed some methods 
for behavioural modification, categorised into three 
kinds: strategies related to food and eating, focusing on 
the mouth, and avoiding strong smell or taste.53 There 
is weak evidence supporting home remedies and little 
evidence for adding artificial flavours during ChT.54 It 
is particularly important to increase saliva production 
through artificial saliva or other options. Bethanechol 
has been shown to stimulate saliva production but it was 
not effective in reducing the incidence of taste alteration 
when taken with RT.55 Regarding the use of acupuncture 
in the treatment of idiopathic dysgeusia, very low- quality 
evidence was insufficient to conclude that acupuncture 
improves taste discrimination in cases of idiopathic 
dysgeusia and hypogeusia.56
Dietary counselling
Two RCTs investigated the role of dietary counselling 
and educational videos: both studies showed that dietary 
counselling had a minor impact on acute dysgeusia but a 
more significant impact on long- term dysgeusia; addition-
ally, it may enhance QoL.57 58
For additional treatment recommendations for 
dysgeusia, see online supplemental material.
Recommendation
 ► For ChT- induced and/or RT- induced dysgeusia, 
patients should be informed about dietary counsel-
ling and self- care strategies (II, B).
XEROSTOMIA (DRY MOUTH)
Xerostomia, also known as dry mouth, may be associated 
with a change in the composition of saliva or reduced sali-
vary flow.
The concept of ‘orphan symptom’ applies to xero-
stomia not because it is a rare AE or a neglected symptom 
without any classifications. In fact, it has been reported 
as one of the most frequent late toxicities, around 40%, 
after head and neck RT.59 The reason to attribute xero-
stomia to the category of orphan symptoms relies on the 
relative paucity of effective treatments to relieve it.60
There are several scales and questionnaires developed 
to evaluate xerostomia. The most frequently used tools 
are the CTCAE and the Radiation/Oncology Toxicity 
Grade (Radiation Therapy Oncology Group) Scales; 
the first one is composed by a subjective and an objec-
tive (saliva flow) assessment, while the second intro-
duces the concept of the response on stimulation. One 
should consider the frequent discrepancies between AEs 
as judged by the physician and by the patients; a correla-
tive study examined the concordance between observer- 
assessed and patient- assessed symptoms and showed that 
the sensitivity of the observer for xerostomia was 74%.61 
It is fundamental to use patient- reported outcome (PRO) 
measures to complement other QoL analyses.
RT technique as well as a dose on the parotid glands 
affect the risk of developing late and persisting dry 
mouth. The first rational preventative measure is to 
limit the volume and radiation dose to the radiosensitive 
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structures. The use of intensity- modulated radiotherapy 
(IMRT) improves late xerostomia and QoL without 
compromising tumour control (I, A).62 With IMRT, the 
schedules commonly used are mean dose of 24–26 Gy 
at least to one parotid and approximately mean dose of 
39 Gy to the submandibular gland (IV, B).63 In addition, 
it has been demonstrated that severe xerostomia can be 
avoided if either the mean dose to both parotid glands 
is <25 Gy or if one parotid gland is spared to a mean 
dose of <20 Gy (II, B).64 Due to the presence of minor 
salivary glands in the oral cavity, sparing the oral cavity 
from unnecessary radiation doses may help decrease both 
acute mucositis and late xerostomia (III, B).65
Other causal agents are radioiodine therapy, ChT 
and targeted treatments (eg, dacomitinib and multitar-
geted angiogenesis inhibitors having the highest risk, 
about 4%–14%) as well as immune checkpoint inhibitors 
(nivolumab and pembrolizumab may induce xerostomia 
in 4%–8% of the cases).66 The role of other concurrent 
drugs employed by the patients should be considered as 
possible causes of xerostomia (such as opioids, antipsy-
chotics, anxiolytics, histamine antagonists and others).67
Treatment
Drugs that act on stimulating muscarinic receptors at the 
surfaces of the salivary gland cells represent a class of ther-
apies. A systematic review and meta- analysis including 736 
patients confirmed that preventive administration of pilo-
carpine, a cholinergic agonist, could increase the unstim-
ulated salivary flow rate during RT, with an advantage 
for only a period of 3–6 months and this may improve 
patient- reported xerostomia at 6 months and possibly 12 
months after treatment has ended (I, B).68 Long- term use 
of systemic pilocarpine 5 mg three times a day or cevime-
line 30 mg three times a day demonstrated an advantage 
in reducing xerostomia in irradiated head and neck 
cancer survivors, with a greater magnitude of benefit for 
pilocarpine.68 However, the clinical significance of the 
obtained benefit is unknown, and the cholinergic AEs 
of the long- term use (bronchospasm, bradycardia, vaso-
dilation and diarrhoea) should be considered in clin-
ical practice (I, C). No evidence exists about the topical 
use of these drugs. Similarly, gustatory and masticatory 
stimulants, such as acidic substances, are only purely 
symptomatic measures, with very limited data available. 
Moreover, lubricants and saliva substitutes are widely 
used with a palliative intent, with insufficient evidence 
regarding their long- term benefit (V, C).69 Acupuncture 
has been studied in two trials in respect to sham/superfi-
cial acupuncture, showing no added benefit in improving 
salivary flow (II, D).70 There is weak evidence for the effi-
cacy of hyperbaric oxygen therapy, because of a scarce 
number of patients treated and the limited follow- up to 
ensure safety of the treatment (IV, C).71
Recommendations
 ► For head and neck RT- induced xerostomia, the 
following treatments are recommended:
 – Pilocarpine 5 mg orally every 8 hours (I, B).
 – Hyperbaric oxygen therapy (IV, C).
COUGH
Cough is a disturbing symptom in patients with advanced 
cancer and may be accompanied by other signs or symp-
toms of disease.72 73 It occurs approximately in 65% of 
patients with advanced lung cancer.73 Cough can often be 
preceded by a sensation of airway irritation often likened 
to itching and referred to as an ‘urge- to- cough’.74
A cough that persists for more than 8 weeks is termed 
‘chronic’.75 In patients with advanced cancer, chronic 
cough can persist for months and remains a difficult 
problem to manage because of the lack of effective anti-
tussive therapies.76 It is mandatory to assess the impact of 
symptom on QoL and to establish the severity, the time 
of onset and the duration of the cough. Cough may be 
described as dry, wet, wheezy, barking and/or bovine 
and may be associated with left recurrent laryngeal nerve 
palsy or abductor paralysis of vocal cords. Other associ-
ated symptoms may be nasal discharge, sputum purulent/
coloured, bronchorrhoea, haemoptysis and dyspnoea. 
Online supplemental table S4 details possible casues of 
cough.
Treatment
The management options include the treatment of 
specific conditions causing cough, and the use of drugs 
to suppress this symptom. In cases when the underlying 
condition is potentially reversible, in chest infection or 
in the case of assumption of ACE inhibitor, cough may 
be reversible.77 78 Many non- drug measures, such as bron-
chopulmonary hygiene therapy, hydration and suction, 
have been adopted, even if evidence on clinical outcome 
measures is lacking. Various protussive agents, for 
example, N- acetylcysteine, hypertonic saline, have been 
used to facilitate the expectoration.77 78 A recent Cochrane 
review has analysed the effectiveness of interventions, 
both pharmacological and non- pharmacological (other 
than ChT and external beam RT), in the management of 
cough in malignant diseases (especially in lung cancer).79
For brachytherapy (II, C), laser therapy (III, C) and 
photodynamic therapy (II, C), eight studies were exam-
ined under this category. Even if some of these studies 
showed a certain grade of benefit in the symptom treat-
ment, final data for these strategies were of low quality, 
with high risk of bias. The advantage of these strategies 
over other available palliation approaches remains to be 
proven.79
There were nine studies of pharmacological treatments 
for cough. These studies had several limitations and bias 
(small sample size, difficulties in data recovering and 
major concern in the assessment of the symptom). The 
products tested included hydropropizine, oxadiazol, 
butamirate citrate linctus, a mixture of codeine with 
phenyltoloxamine and dihydrocodeine, two different 
Chinese herbal preparations, morphine and codeine, 
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levodropropizine and dihydrocodeine, sodium cromo-
glycate and dihydrocodeine. In the absence of RCTs in 
this field, no firm conclusions could be drawn for any 
of the pharmacological treatments presented, although 
butamirate linctus, codeine (60 mg), morphine, dihydro-
codeine (10 mg), cromoglycate and hydropropizine or 
levodropropizine seemed to exercise some positive effect 
on cough related to lung cancer (IV, C).79 80 The effect 
of these latter treatments should be balanced with the 
potential side effects, including nausea, dizziness or diar-
rhoea with butamirate linctus or drowsiness and consti-
pation with opioids.79 The effect of sodium cromoglycate 
in the absence of asthma or other respiratory pathology 
may be limited.
A double- blind, placebo- controlled trial randomised 
adults with refractory chronic cough to receive 
gabapentin (maximum tolerable per day dose of 1800 
mg) or matching placebo for 10 weeks. The primary end 
point was a change in cough- specific QoL. Gabapentin 
significantly improved cough- specific QoL compared with 
placebo. The treatment of refractory chronic cough with 
gabapentin (per day dose of 1800 mg) may be suggested 
to treat cough in oncological patients (II, C).81
Several reported outcomes for the use of gabapentin 
warrant further investigation as a potential role of antiepi-
leptics in this field. At the time of this review of the litera-
ture, there is insufficient evidence on the management of 
cough with gabapentin in patients with cancer.82
For the indicative doses for antitussives, demulcents 
and topical anaesthetics, please refer to online supple-
mental table S5.
Recommendations
 ► For coughs related to lung cancer, the following treat-
ments are recommended:
 – Codeine 30–60 mg per day or morphine low doses, 
dihydrocodeine 10 mg orally every 12 hours, cro-
moglycate 10 mg four times a day inhaled via nebu-
lisation and hydropropizine or levodropropizine 
75 mg three times a day (IV, C).
 – Gabapentin for refractory chronic cough (1800 mg 
per day) (II, C).
RECTAL TENESMUS
Rectal tenesmus is the painful sensation of incomplete 
evacuation of the bowel, resulting in the sensation of 
needing to defaecate many times a day. It represents a 
distressing symptom that significantly affects QoL.83
The real incidence and prevalence of tenesmus among 
a cancer population, especially in the palliative care 
setting, remain unknown. In patients with recurrent rectal 
carcinoma, the reported prevalence is around 14%,84 but 
there are few reported statistics about this symptom and 
probably the real prevalence may be higher.
The pathophysiology of tenesmus is not fully under-
stood. It is possible that direct tumour invasion of 
the sacral plexus results in neuropathic pain; tumour 
inflammation transmits pain through somatic afferents 
and smooth muscle contraction transmits pain through 
autonomic afferents.85
Pelvic malignant diseases are frequently associated with 
rectal tenesmus directly by compression and/or tissue 
infiltration and indirectly as an AE of locoregional treat-
ments (surgery, RT, etc).
Diagnosis of rectal tenesmus caused by RT or cancer 
invasion is typically based on patients’ medical history 
and clinical examination. The temporal relationship 
between timing of administration of radiation in relation 
to the symptoms and signs is often sufficient to clinically 
document the condition.
There is no known measurement scale for rectal 
tenesmus in the palliative setting. Rectal mucositis, anal 
mucositis, abdominal pain and constipation are terms 
that can be scored separately in the CTCAE V.5.0 within 
the system organ class ‘Gastrointestinal Disorders’, while 
the global estimate of the rectal tenesmus can be clas-
sified in the section ‘Gastrointestinal Disorders- Other, 
specify’ as follows:
 ► Grade 1: symptomatic or mild symptoms; clinical 
or diagnostic observations only; intervention not 
indicated.
 ► Grade 2: moderate; minimal, local or non- invasive 
intervention indicated; limiting age- appropriate 
instrumental activities of daily living (ADLs).
 ► Grade 3: severe or medically significant but not imme-
diately life- threatening; hospitalisation or prolonga-
tion of existing hospitalisation indicated; disabling; 
limiting self- care ADLs.
 ► Grade 4: life- threatening consequences; urgent inter-
vention indicated.
 ► Grade 5: death.
Rectal tenesmus is a subjective experience and therefore 
assessment should include PROs without filtering by a 
healthcare professional.
Among clinical trials and systematic reviews, the primary 
outcome measure was reduction in severity of tenesmus 
(measured by numerical rating scales, categorical scales: 
complete, partial and no relief, reduced sensation to 
defaecate or a patient’s account of improvement).83
Treatment
The management should be focused on the cause of 
tenesmus, and not on the tenesmus itself as a symptom, 
by treating the underlying malignancy with surgery, ChT 
and RT.
In patients without these therapeutic options due to 
disease status or patient status, symptom control is chal-
lenging. Symptomatic management of tenesmus has 
been frequently reported in the palliative care setting 
of patients with rectal cancer.86 Since tenesmus is largely 
unresponsive to strong opioids, benzodiazepines and 
phenothiazines are used to treat this symptom but 
evidences of their efficacy remain poor.87 Pharmacolog-
ical intervention may be the better approach in the palli-
ative setting, but other studies have analysed anaesthetic 
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and endoscopic laser therapy (ELT) interventions with 
promising results.
Several trials about pharmacological interventions in 
the management of tenesmus are reported in literature. 
In some cases, authors reported retrospective data with 
very small case series. For all these study types, the quality 
is very poor. All reported papers were conducted among 
patients with colorectal or other pelvic tumours (see 
online supplemental table S6).
Lumbar sympathectomy was also reported as an inter-
esting approach for the management of tenesmus, 
resulting in 10/12 patients gaining complete relief with 
low side effects (temporary hypotension occurred in one 
patient). Resolution/reduction in severity of tenesmus 
was also seen in three patients who underwent neurol-
ytic superior hypogastric plexus block, with no AEs.88 Due 
to low quality of evidence of these studies and very old 
data, the authors do not recommend this approach in 
the palliative setting (V, D). ELT was also reported as a 
possible approach to management of tenesmus. Several 
reports with very low quality of evidence resulted in 
gaining complete relief from tenesmus. Due to important 
side effects including blood or mucus from rectum, rectal 
discomfort and death in five cases, this approach is not 
recommended in the palliative setting (V, E).89
Due to the lower quality of evidence and the absence of 
RCTs, a first- choice treatment cannot be recommended. 
Several case series report anecdotal approaches with 
drugs used for symptoms (pain) management.
It is reported that opioids are effective for tenesmus 
management among patients with cancer.86 90 One 
patient experienced significant pain relief with an opioid 
rotation from morphine to methadone. A second patient 
had tenesmus resolution and decreased systemic opioid 
requirements after rectal administration of morphine gel. 
One patient on opioids for a protruding rectal cancer 
experienced immediate and sustained analgesia after the 
application of topical lidocaine and prilocaine. Another 
patient with rectal pain and tenesmus refractory to 
opioids, ketamine and midazolam was treated with rectal 
bupivacaine.91 92
Four patients received a vasodilator for tenesmus. 
Three out of four patients experienced significant relief 
of tenesmus with nifedipine.93 Two patients had reduced 
pain, tenesmus and opioid requirements with diltiazem.94 
This approach was well tolerated but confounded by the 
use of other analgesics.
Recommendations
 ► For malignancy- associated (colorectal or other pelvic 
tumour) rectal tenesmus, the following treatments 
are recommended:
 – Diltiazem orally 30 mg every 6 hours (V, C).
 – 2% topical methadone 2.5 mg every hour or 2.5 mg 
orally every 8 hours with titration (V, C).
 – Nifedipine 10–20 mg orally two times per day (V, 
C).
HICCUP
Hiccups are uncontrolled spasms of the diaphragm 
between normal breaths. A hiccup can be defined as a 
quick, involuntary inhalation that follows a spasm of the 
diaphragm and is suddenly checked by closure of the 
glottis, producing a short, relatively sharp sound. Hiccups 
are defined as acute if the episode lasts for minutes to 
hours, persistent if the episode lasts for more than 48 
hours and intractable in instances in which the hiccups 
last for more than 1 month.95
There are several potential causes of hiccups, most of 
which have gastrointestinal origin and include vagal and 
phrenic nerve stimulation. Other causes involve CNS 
disorders, metabolic disorders, psychogenic disorders and 
drugs. Metabolic causes of hiccups include hypokalaemia, 
hypocalcaemia, hypocarbia (hyperventilation) and 
uraemia. Interestingly, some of the same medications used 
to treat hiccups have also, at times, been implicated in their 
cause (eg, steroids, benzodiazepines, opioids and antido-
paminergics). Hiccups, particularly those of non- CNS 
origin, are more common in men. Patients with advanced 
cancer can have more than one cause for hiccups. Several 
drugs can induce hiccups such as dexamethasone, diaz-
epam, opioids, antibiotics, perphenazine, short- acting 
barbiturates and ChT agents (eg, cisplatin, carboplatin, 
cyclophosphamide, docetaxel, etoposide, gemcitabine, 
irinotecan, paclitaxel, vindesine, vinorelbine, ifosfamide, 
levofolinate), and aprepitant with a reported incidence of 




Baclofen (5–20 mg three times per day orally) has 
been used in case reports with a low number of treated 
patients. This drug is a GABA analogue, an inhibitory 
neurotransmitter that acts on presynaptic motor neurons 
at the spinal level and produces a central antispastic 
response. Sedation is the most common side effect, but 
insomnia, dizziness, ataxia and mental confusion can also 
occur. Baclofen seems to improve the severity but not the 
frequency of hiccups (IV, C).96
Gabapentin
In a retrospective study, 43 patients were initially treated 
with 300 mg gabapentin, increasing the dose as needed 
until 1200 mg per day. There was an improvement in 83% 
of the cases, with minimal side effects (mainly somno-
lence) (IV, C).96
Chlorpromazine
Chlorpromazine has been used in a case report with 50 
patients97 and in a retrospective chart review of 8 patients. 
Chlorpromazine effectiveness in the treatment of hiccups 
is probably due to the antidopaminergic effect, with 
strong antiemetic results as well as anticholinergic activity, 
resulting in important sedative and antihiccup effect (IV, 
C).
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Midazolam
The use of benzodiazepine midazolam (10–60 mg/per 
day) has been reported in two case reports, with three 
patients in total. Midazolam exerts a central action, along 
with anticonvulsant and general sedation effects with 
amnesia, allowing a tonic depressant effect on striated 
muscle reflexes, and reducing the number of hiccup 
episodes. Midazolam should only be considered in very 
selected patients with very refractory hiccups, due to its 
important side effects (V, C).98
Haloperidol
Haloperidol (1.5–3 mg at night orally) has been shown to 
be effective via dopamine antagonism. It might be better 
tolerated than chlorpromazine (V, C).98
Non-pharmacological treatments
Peppermint
Peppermint facilitates belching by relaxing the lower 
oesophageal sphincter. Although this has been noted as 
a potential treatment of hiccup, there is little evidence in 
using it along with a prokinetic agent, as their effects are 
somewhat opposite (V, D).99
Acupuncture
Acupuncture has long been used to treat hiccups in China. 
Acupuncture is a well- known alternative therapy practised 
worldwide, but its effectiveness for treating hiccups has 
rarely been tested. Few rigorous RCTs evaluating the 
effects of acupuncture for hiccups in patients with cancer 
are actually available, and these studies provide limited 
evidence of the superiority of acupuncture over conven-
tional therapies for cancer- related hiccups (IV, D).100
Steroid rotation
Dexamethasone, one of the key medications for the 
prevention of ChT- induced nausea and vomiting (CINV), 
may cause hiccups as an AE. In a randomised, multi-
centre, phase III trial, hiccup intensity was significantly 
lower when the antiemetic corticosteroid was rotated 
from dexamethasone to methylprednisolone without a 
change in emesis intensity.101
It has been demonstrated in different case series that 
switching dexamethasone to an equipotent dosage of 
either methylprednisolone or prednisolone resolved the 
hiccups while maintaining adequate control of CINV.
Steroid rotation for the treatment of steroid- induced 
hiccups is recommended (II, B).98 101
Recommendations
 ► For ChT- induced, steroid- induced or CNS damage, 
the following treatments are recommended:
 – Baclofen 5–20 mg three times a day orally (IV, C).
 – Gabapentin 300–1200 mg per day orally (IV, C).
 – Chlorpromazine 10–25 mg orally or intravenously 
(V, C).
 – Haloperidol 1.5–3 mg at night orally (V, C).
 – Steroid rotation (II, B).
 – Midazolam 10–60 mg per day (V, C).
 – Haloperidol 1.5–3 mg at night orally (V, C).
 – Acupuncture (IV, D).
RESTLESS LEGS SYNDROME
RLS, is a neurological condition that causes sleep and 
movement disorders, in particular as an uncontrollable 
desire to move the limbs. It is usually associated with 
paresthesias and/or dysesthesias with motor restlessness. 
RLS- related symptoms start or worsen at rest and improve 
with activity. Worsening of symptoms in the evening 
and/or at night often results in disturbance of sleep and 
daytime tiredness.
RLS is generally considered idiopathic (primary) or 
symptomatic (secondary). The primary form (60%–80% 
of all RLS) might be better defined as cryptogenic, indi-
cating that in most cases the aetiology and pathogenesis 
are uncertain. Secondary or RLS- associated conditions 
include end- stage renal disease, iron deficiency (with 
or without anaemia), thyroid disorders, neuropathies 
and radiculopathies, rheumatoid arthritis, myelopa-
thies, syringomyelia, Parkinson’s disease and pregnancy. 
However, there is still little understanding of this disorder 
and many patients with cancer suffer from RLS symptoms 
without a diagnosis from the medical profession. One 
recent study showed that even though 45% of the patients 
interviewed had moderate- to- severe symptoms of RLS, 
none of them had been diagnosed or treated.102
Sleep disturbances are frequent in patients with cancer 
during ChT; the contributory role of RLS in this setting 
has been investigated in a prospective trial that included 
173 patients with cancer. The authors found a direct 
correlation between sleep disturbances and RLS in 20% 
of patients.103
Few concrete conclusions can be made about RLS epide-
miology in patients with cancer because this disorder is 
underdiagnosed and poorly understood.
The four criteria that are essential for diagnosis of RLS 
are described in online supplemental table S7.
Treatment
At present there are no studies on RLS conducted in the 
oncological population: the therapeutic indications are 
based on trials conducted in mixed populations.
The therapeutic choice is based on three factors: iron 
status, clinical intensity of the symptoms and indica-
tions for comorbid conditions. Iron status should always 
be evaluated even in very mild cases. Iron deficiency 
has been implicated in the pathophysiology of RLS, 
based on the clinical findings that patients with iron 
deficiency have a higher frequency of RLS (30%) than 
those without deficiency and that severity of RLS symp-
toms correlates with the severity of iron deficiency.104
Low iron stores can usually be replenished with 
prolonged oral iron administration (ferrous sulfate 
325 mg two times per day) if it is tolerated (II, C).105 
Clinical intensity of the symptoms must be carefully 
evaluated. Mild RLS can often be managed by lifestyle 
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adjustments without any medication, except for oral 
iron, if indicated. moderate- to- severe RLS classified 
as chronic and persistent usually requires daily medi-
cations. Comorbid conditions that could produce or 
exacerbate symptoms such as depression, anxiety disor-
ders, neuropathy and iron deficiency must be carefully 
considered.106 Since the 1990s, dopaminergic therapies 
have been considered the first- line treatment for adults 
with RLS, both for sleep disturbance and for daytime 
symptoms. In the past 5 years, treatment efficacy of 
dopamine agonists (such as pramipexole, ropinirole 
and rotigotine) approved by the US Food and Drug 
Administration and the European Medicines Agency 
for the treatment of RLS have been further confirmed 
in analyses of the drugs in RCTs.107 108 Although this 
class of drugs is generally well tolerated, treatment effi-
cacy diminishes in many patients over time. Moreover, 
dopaminergic drugs can specifically worsen overall 
disease severity through a process called augmentation 
(the intensifying of symptoms or manifestation earlier 
in the day after a period of successful dopaminergic 
treatment). This RLS augmentation can be severe and 
appears to happen gradually with continued use of the 
medications.
Alpha-2-delta ligands
Seven RCTs that examined the efficacy of gabapentin 
enacarbil in RLS have been published that qualify for 
inclusion. These seven high- quality studies, ranging in 
duration from 2 weeks to 12 weeks, indicate that gabap-
entin enacarbil is efficacious up to 12 weeks at a dose of 
1200 mg. A high rate of dropouts compared with placebo 
is evident in several studies (I, B).107
Pregabalin is another efficacious medication for the 
treatment of moderate- to- severe idiopathic RLS when 
taken at doses between 150 mg/day and 450 mg/day, 
1–3 hours before bedtime. Three RCTs which examined 
the efficacy of pregabalin in more than 900 patients with 
RLS over 6–52 weeks have been published that qualify for 
inclusion. The most frequently reported AEs were dizzi-
ness, somnolence, fatigue and headache (I, B).107 Given 
that pregabalin is metabolised renally, lower doses may be 
necessary in older populations.
Non-ergot-derived dopamine agonists
Several published RCTs about the use of rotigotine in 
the treatment of RLS have been analysed (104). There 
is sufficient evidence to conclude that a rotigotine trans-
dermal patch is clinically useful for the management of 
RLS in patients with moderate- to- severe clinical symp-
toms (I, A).
There is also evidence that pramipexole at doses of 0.25 
mg, 0.50 mg and 0.75 mg is efficient for the management 
of RLS in patients with moderate- to- severe clinical symp-
toms (I, B).109
Sufficient evidences support another dopamine agonist 
ropinirole as clinically useful for both RLS symptoms 
and improving sleep in patients with moderate- to- severe 
clinical symptoms. One trial comparing ropinirole with 
gabapentin found that they were equally efficient in 
treating RLS, but this study only included 16 patients who 
were treated for 4 weeks (I, B).110
Benzodiazepines
Benzodiazepines can induce and maintain sleep and are 
thought to be beneficial for people with RLS. Although 
benzodiazepines, particularly clonazepam, are used to 
treat RLS symptoms, a systematic review done by the 
American Academy of Sleep Medicine stated that benzo-
diazepines should not be used as a first- line treatment, 
although they could be used as a coadjuvant therapy.111
It has been shown that clonazepam can alleviate 
sensory symptoms and favour/induce sleep. Randomised 
controlled studies among non- cancer populations 
demonstrated an improvement in patients’ QoL (II, C). 
Given the lack of knowledge about the role of clonaz-
epam or other benzodiazepines in the treatment of RLS, 
only well- designed clinical trials will answer this question. 
This is of relevance, since clonazepam is suggested to be 
beneficial for the control of augmentation, an emergent 
clinical problem associated with the use of dopaminergic 
agonists for the treatment of RLS.112
Despite limited data on the QoL improvement with 
clonazepam, the last Cochrane systematic review about 
efficacy and safety of benzodiazepines showed that there 
were no data to support or refute the use of these drugs 
to treat RLS symptoms (II, C).111
Although some features of these drugs may benefit 
people with RLS, others might act in the opposite way: for 
instance, this class of drugs may act as opioid antagonists 
attenuating opioid antinociception.111
Opioids
Opioids are most commonly used for RLS in the first 
steps of treatment failure. In the opioid class of drugs, 
oxycodone/naloxone combination is efficacious when 
used at low doses two times per day for improving both 
daytime and night- time symptoms in patients with severe 
or refractory RLS.
A double- blind, randomised, placebo- controlled trial 
showed that prolonged release oxycodone/naloxone was 
effective and safe for RLS treatment after primary treat-
ment medications had failed (II, B).113
However, commonly occurring AEs such as fatigue, 
constipation, nausea, induction or worsening of sleep- 
disordered breathing and the potential for misuse 
should be taken into account. Oxycodone/naloxone 
is licensed for severe RLS as a second- line therapy in 
Europe.114
The absence of ongoing studies on opioids, as on 
benzodiazepines, may reflect the lack of interest of clin-
ical researchers in this class of drugs for the treatment of 
RLS.
Online supplemental table S8 summarises the most 
commonly used drugs for RLS (in non- cancer population).
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Recommendations
 ► For ChT- induced, steroid- induced or CNS damage, 
the following treatments are recommended:
 – Gabapentin enacarbil 1200 mg per day (I, B).
 – Pregabalin 100–450 mg per day (I, B).
 – Rotigotine patch 1–3 mg per day (I, A).
 – Pramipexole 0.25 mg, 0.5 mg or 0.75 mg per day 
(I, B).
 – Ropinirole 0.78–4.6 mg per day (I, B).
 – Clonazepam 0.25 mg at bedtime, maximum dose 
3–4 mg per day in divided doses (II, C).
 – Prolonged- release oxycodone/naloxone two times 
per day (oxycodone 10–40 mg and naloxone 5–20 
mg two times per day) (II, B).
METHODOLOGY
These clinical practice guidelines were developed in 
accordance with the ESMO standard operating proce-
dures for Clinical Practice Guidelines development 
http://www. esmo. org/ Guidelines/ ESMO- Guidelines- 
Methodology. The relevant literature has been selected 
by the expert authors. LoE and GoR have been applied 
using the system shown in online supplemental table 
S9115. Statements without grading were considered justi-
fied standard clinical practice by the experts and the 
ESMO faculty. This manuscript has been subjected to an 
anonymous peer review process.
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